Clinical trial
Iparomlimab and Tuvonralimab Combined With 2 or 4 Cycles of Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC
NCT07129161 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Iparomlimab and Tuvonralimab Combined With 2 or 4 Cycles of Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC
- Lead sponsor
- Sun Yat-sen University
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- August 31, 2025
- Completion date
- December 31, 2027
- Enrollment
- 66 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.